PYY[3-36] Administration Decreases the Respiratory Quotient and Reduces Adiposity in Diet-Induced Obese Mice
Authors:
- Sean H. AdamsSASean H. Adams
- Svetlana E NikoulinaSNSvetlana E Nikoulina
- Julie A HoytJHJulie A Hoyt
Open Access
- 1 January 2006
- journal article
- research article
- Published by Elsevier in The Journal of Nutrition
- Vol. 136 (1) , 195-201
Abstract
In rodents, weight reduction after peptide YY[3-36] (PYY[3-36]) administration may be due largely to decreased food consumption. Effects on other processes affecting energy balance (energy expenditure, fuel partitioning, gut nutrient uptake) remain poorly understood. We examined whether s.c. infusion of 1 mg/(kg·d) PYY[3-36] (for up to 7 d) increased metabolic rate, fat combustion, and/or fecal energy loss in obese mice fed a high-fat diet. PYY[3-36] transiently reduced food intake (e.g., 25–43% lower at d 2 relative to pretreatment baseline) and decreased body weight (e.g., 9–10% reduction at d 2 vs. baseline) in 3 separate studies. Mass-specific metabolic rate in kJ/(kg·h) in PYY[3-36]–treated mice did not differ from controls. The dark cycle respiratory quotient (RQ) was transiently decreased. On d 2, it was 0.747 ± 0.008 compared with 0.786 ± 0.004 for controls (P < 0.001); light cycle RQ was reduced throughout the study in PYY[3-36]–treated mice (0.730 ± 0.006) compared with controls (0.750 ± 0.009; P < 0.001). Epididymal fat pad weight in PYY[3-36]–treated mice was ∼50% lower than in controls (P < 0.01). Fat pad lipolysis ex vivo was not stimulated by PYY[3-36]. PYY[3-36] decreased basal gallbladder emptying in nonobese mice. Fecal energy loss was negligible (∼2% of ingested energy) and did not differ between PYY[3-36]–treated mice and controls. Thus, negative energy balance after PYY[3-36] administration in diet-induced obese mice results from reduced food intake with a relative maintenance of mass-specific energy expenditure. Fat loss and reduced RQ highlight the potential for PYY[3-36] to drive increased mobilization of fat stores to help meet energy requirements in this model.Keywords
This publication has 30 references indexed in Scilit:
- Intravenous Infusion of Peptide YY(3–36) Potently Inhibits Food Intake in RatsEndocrinology, 2005
- Effects of Peptide YY[3–36] on Short-Term Food Intake in Mice Are Not Affected by Prevailing Plasma Ghrelin LevelsEndocrinology, 2004
- Effects of PYY[3–36] in rodent models of diabetes and obesityInternational Journal of Obesity, 2004
- Peptide YY3–36Inhibits Food Intake in Mice through a Melanocortin-4 Receptor-Independent MechanismEndocrinology, 2004
- Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY3–36 but resistant to ghrelinInternational Journal of Obesity, 2004
- Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY 3-36Proceedings of the National Academy of Sciences, 2004
- Inhibition of Food Intake in Obese Subjects by Peptide YY3–36New England Journal of Medicine, 2003
- Gut hormone PYY3-36 physiologically inhibits food intakeNature, 2002
- Two molecular forms of Peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1–36 and PYY 3–36Regulatory Peptides, 1994
- Human distribution and release of a putative new gut hormone, peptide YYGastroenterology, 1985